Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
Authors
Orkin, C; Antinori, A; Rockstroh, J; Guillen, SM; Martorell, C; Molina, J-M; Lazzarin, A; Maggiolo, F; Yazdanpanah, Y; Andreatta, KCollections
- Centre for Immunobiology [1121]